Letter Ahead of print
PubMed: 41297185 DOI: 10.1016/j.annder.2025.103444
Neoadjuvant ipilimumab and nivolumab for resectable stage II mucosal melanoma.
Ann Dermatol Venereol 153(1):103444
Authors: M Amiot, C Halimi, A Chaud, A Guyard, K Ben-Ali, C Faucon, F Brunet-Possenti
Affiliations
- Department of Dermatology, Hôpital Bichat AP-HP, Université Paris Cité, Paris, France.
- Department of Head and Neck Surgery, Hôpital Bichat AP-HP, Paris, France.
- Department of Pathology, Hôpital Bichat AP-HP, Paris, France.
- Department of Nuclear Medicine, Hôpital Bichat AP-HP, Paris, France.
- Department of Dermatology, Hôpital Bichat AP-HP, Université Paris Cité, Paris, France.
MeSH
Sexually Transmitted Diseases, Melanoma, Nivolumab, Ipilimumab, Dermatology